Presents the complicated process of CNS drug development in a way that is engaging and informative for professionals and students.Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Preface; 1. History of CNS drug development Sheldon H. Preskorn; 2. Regulatory issues Gwen L. Zornberg; 3. Pre-clinical development Alan J. Cross and Frank D. Yocca; 4. Phase I trials: from traditional to newer approaches Matthew Macaluso, Michael Krams and Sheldon H. Preskorn; 5. Phase II development and the path to personalized medicine in CNS disease Douglas E. Feltner and Kenneth R. Evans; 6. CNS drug development - Phase III Judith Dunn, Penny Randall and Amir Kalali; 7. Statistics issues relevant to CNS drug development Craig H. Mallinckrodt, William R. Prucka and Geert Molenberghs; 8. Clinical trials management at company level Nuala Murphy; 9. Clinical trials management at the site level Joseph Kwentus; 10. Medical writing for CNS indications Ginette Nachman; 11. Dissemination of clinical trial information: multiple audiences, multiple formats Leslie Citrome; 12. The importance of treating cognition in schizophrenia and other severe mental illnesses: background, strategies, and findings to date Philip D. Harvey and Richard S. E. Keefe; 13. Leveraging disruptive technologies to drive innovation in CNS clinical drug development Penny Randall, Judith Dunn and Amir Kalali; Index.
Preface; 1. History of CNS drug development Sheldon H. Preskorn; 2. Regulatory issues Gwen L. Zornberg; 3. Pre-clinical development Alan J. Cross and Frank D. Yocca; 4. Phase I trials: from traditional to newer approaches Matthew Macaluso, Michael Krams and Sheldon H. Preskorn; 5. Phase II development and the path to personalized medicine in CNS disease Douglas E. Feltner and Kenneth R. Evans; 6. CNS drug development - Phase III Judith Dunn, Penny Randall and Amir Kalali; 7. Statistics issues relevant to CNS drug development Craig H. Mallinckrodt, William R. Prucka and Geert Molenberghs; 8. Clinical trials management at company level Nuala Murphy; 9. Clinical trials management at the site level Joseph Kwentus; 10. Medical writing for CNS indications Ginette Nachman; 11. Dissemination of clinical trial information: multiple audiences, multiple formats Leslie Citrome; 12. The importance of treating cognition in schizophrenia and other severe mental illnesses: background, strategies, and findings to date Philip D. Harvey and Richard S. E. Keefe; 13. Leveraging disruptive technologies to drive innovation in CNS clinical drug development Penny Randall, Judith Dunn and Amir Kalali; Index.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826
